Search

Your search keyword '"Colorado Araujo, Mercedes"' showing total 5 results
Start Over Author "Colorado Araujo, Mercedes" Database OpenAIRE
5 results on '"Colorado Araujo, Mercedes"'

1. Autologous Hematopoietic Cell Transplantation For Relapsed Multiple Myeloma Performed With Stem Cells Re-Mobilised Following A Prior AUTO-HCT - A Retrospective Study on Behalf of EBMT CMWP

Author

Byrne, Jennifer, Snowden, John A., Crawley, Charles, Colorado Araujo, Mercedes, de Wreede, Liesbeth, Passweg, Jakob, Van Gorkom, Gwendolyn, GÜRMAN, GÜNHAN, Zinger, Nienke, Gras, Luuk, Yakoub-Agha, Ibrahim, Schoenland, Stefan, Tilly, Herve, BEKSAÇ, MERAL, Hayden, Patrick, Bulabois, Claude Eric, Arat, Mutlu, Basak, Grzegorz, Pouli, Anastasia, Poire, Xavier, Wilson, Keith M. O., Lioure, Bruno, Schroyens, Wilfried, ÖZKURT, ZÜBEYDE NUR, and Drozd-Sokolowska, Joanna

Published
2021

2. Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice

Author

Garcia-Gutierrez, Valentin, Luna, Alejandro, Alonso-Dominguez, Juan M., Estrada Barreras, Natalia, Boque, Concepcion, Xicoy, Blanca, Giraldo, Pilar, Angona, Anna, Álvarez Larrán, Alberto, Sanchez-Guijo, Fermin, Ramírez, María José, Mora, Elvira, Vélez, Patricia, Rosell, Ana, Colorado Araujo, Mercedes, Cuevas, Beatriz, Sagüés, Miguel, Cortés, Montserrat, Pérez Encinas, Manuel, Casado Montero, Luis Felipe, Moreno Vega, Melania, Serrano, Luis, Gomez, Valle, Garcia-Hernandez, Carmen, Lakhwani, Sunil, Paz Coll, Antonio, De Paz, Raquel, Suarez-Varela, Sara, Fernandez-Ruiz, Andrés, Perez Lopez, Raul, Ortiz-Fernández, Almudena, Jiménez-Velasco, Antonio, Steegmann-Olmedillas, Juan Luis, Hernandez-Boluda, Juan Carlos, Universitat Autònoma de Barcelona, [Garcia-Gutiérrez V, Luna A] Hematology, Hospital Universitario Ramón y Cajal. IRYCIS, Madrid, Spain. [Alonso-Dominguez JM] Hospital Universitario Fundación Jiménez Díaz, Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), UAM, Madrid, Spain. [Estrada N, Xicoy B] Institut Català d’Oncologia, Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain. [Boque C] Institut Català d’Oncologia – L’Hospitalet de Llobregat, L’Hospitalet de Llobregat, Spain. [Cortes M] Hospital General de Granollers, Granollers, Spain, and Departament de Salut

Subjects
Adult, Male, Niacinamide, medicine.medical_specialty, Heterocyclic Compounds::Acids, Heterocyclic::Nicotinic Acids::Niacinamide [CHEMICALS AND DRUGS], MEDLINE, Fusion Proteins, bcr-abl, Drug development, Hemic and Lymphatic Diseases::Hematologic Diseases::Bone Marrow Diseases::Myeloproliferative Disorders::Leukemia, Myelogenous, Chronic, BCR-ABL Positive [DISEASES], lcsh:RC254-282, Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protein Kinase Inhibitors [CHEMICALS AND DRUGS], Young Adult, Text mining, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, hemic and lymphatic diseases, Correspondence, compuestos heterocíclicos::ácidos heterocíclicos::ácidos nicotínicos::niacinamida [COMPUESTOS QUÍMICOS Y DROGAS], Medicine, In real life, Humans, Intensive care medicine, Protein Kinase Inhibitors, Aged, Aged, 80 and over, Leucèmia mieloide crònica - Tractament, business.industry, acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::inhibidores enzimáticos::inhibidores de proteínas cinasas [COMPUESTOS QUÍMICOS Y DROGAS], Myeloid leukemia, Hematology, Middle Aged, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Tiroxina - Inhibidors, Clinical Practice, Treatment Outcome, Oncology, Molecularly targeted therapy, Proteïna quinasa CK2, Pyrazoles, Female, enfermedades hematológicas y linfáticas::enfermedades hematológicas::enfermedades de la médula ósea::trastornos mieloproliferativos::leucemia mielogenosa crónica BCR-ABL positiva [ENFERMEDADES], business
Abstract

Chronic myeloid leukemia; Asciminib; Treatment Leucemia mieloide crónica; Asciminib; Tratamiento Leucèmia mieloide crònica; Asciminib; Tractament Despite the excellent overall survival (OS) of chronic myeloid leukemia (CML) patients, a significant proportion will fail currently available tyrosine-kinase inhibitors (TKIs) due to resistance or intolerance. Intolerant patients are usually managed successfully with alternative second-generation tyrosine-kinase inhibitors (2GTKIs). However, more than half of the patients will eventually discontinue second-line treatment due to loss of response or toxicity. Ponatinib is an effective drug in the setting of resistance to 2GTKIs, however with life-threatening side effects and varying responses. Asciminib is a first-in-class STAMP (Specifically Targeting the ABL Myristoyl Pocket) inhibitor that potently and specifically inhibits BCR-ABL1 via binding to a pocket distinct from the ATP binding site of the kinase. Asciminib has the potential to overcome resistance to prior TKIs, and also offers the possibility of dual inhibition of BCR-ABL1 in combination with ATP-binding TKIs. Asciminib has been evaluated in a phase I study in patients with Ph-positive leukemia failing prior TKIs, with promising results. Our aim is to share the first data on the use of asciminib in CML patients in clinical practice, allowed by Novartis under a managed-access program (MAP).

Published
2021

3. Long-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients With Intermediate Cytogenetic Risk Acute Myeloid Leukemia: A PETHEMA Study

Author

Rodríguez-Arbolí, Eduardo, Martínez-Cuadrón, David, Rodríguez-Veiga, Rebeca, Carrillo-Cruz, Estrella, Gil-Cortés, Cristina, Serrano-López, Josefina, Bernal Del Castillo, Teresa, Martínez-Sánchez, María Del Pilar, Rodríguez-Medina, Carlos, Vidriales, Belén, Bergua, Juan Miguel, Benavente, Celina, García-Boyero, Raimundo, Herrera-Puente, Pilar, Algarra, Lorenzo, Sayas-Lloris, María José, Fernández, Rosa, Labrador, Jorge, Lavilla-Rubira, Esperanza, Barrios-García, Manuel, Tormo, Mar, Serrano-Maestro, Alfons, Sossa-Melo, Claudia Lucía, García-Belmonte, Daniel, Vives, Susana, Rodríguez-Gutiérrez, Juan Ignacio, Albo-López, Carmen, Garrastazul-Sánchez, María Paz, Colorado-Araujo, Mercedes, Mariz, José, Sanz, Miguel Ángel, Pérez-Simón, José Antonio, Montesinos, Pau, PETHEMA (Programa Español de Tratamientos en Hematología) and GETH (Grupo Español de Trasplante Hematopoyético y Terapia Celular) Cooperative Groups, Instituto de Salud Carlos III, and Centro de Investigación Biomédica en Red Cáncer (España)

Subjects
Oncology, medicine.medical_specialty, NPM1, European LeukemiaNet, Internal medicine, CEBPA, Immunology and Allergy, Medicine, Humans, Transplantation, Homologous, Cumulative incidence, Transplantation, Acute myeloid leukemia, business.industry, Remission Induction, Hematopoietic Stem Cell Transplantation, Myeloid leukemia, Cell Biology, Hematology, Confidence interval, Allogeneic stem cell transplant, Leukemia, Myeloid, Acute, Autologous stem cell transplant, Cytogenetic Analysis, Molecular Medicine, Stem cell, business, Nucleophosmin
Abstract

PETHEMA (Programa Español de Tratamientos en Hematología) and GETH (Grupo Espa~nol de Trasplante Hematopoyético y Terapia Celular) Cooperative Groups, Acute myeloid leukemia (AML) with intermediate risk cytogenetics (IRcyto) comprises a variety of biological entities with distinct mutational landscapes that translate into differential risks of relapse and prognosis. Optimal postremission therapy choice in this heterogeneous patient population is currently unsettled. In the current study, we compared outcomes in IRcyto AML recipients of autologous (autoSCT) (n = 312) or allogeneic stem cell transplantation (alloSCT) (n = 279) in first complete remission (CR1). Molecular risk was defined based on CEBPA, NPM1, and FLT3-ITD mutational status, per European LeukemiaNet 2017 criteria. Five-year overall survival (OS) in patients with favorable molecular risk (FRmol) was 62% (95% confidence interval [CI], 50-72) after autoSCT and 66% (95% CI, 41-83) after matched sibling donor (MSD) alloSCT (P = .68). For patients of intermediate molecular risk (IRmol), MSD alloSCT was associated with lower cumulative incidence of relapse (P < .001), as well as with increased nonrelapse mortality (P = .01), as compared to autoSCT. The 5-year OS was 47% (95% CI, 34-58) after autoSCT and 70% (95% CI, 59-79) after MSD alloSCT (P = .02) in this patient subgroup. In a propensity-score matched IRmol subcohort (n = 106), MSD alloSCT was associated with superior leukemia-free survival (hazard ratio [HR] 0.33, P = .004) and increased OS in patients alive 1 year after transplantation (HR 0.20, P = .004). These results indicate that, within IRcyto AML in CR1, autoSCT may be a valid option for FRmol patients, whereas MSD alloSCT should be the preferred postremission strategy in IRmol patients., Supported by a Río Hortega academic clinical fellowship (CM19/00194) from the Instituto de Salud Carlos III, Spain (E.R.A.). Additional funding has been provided by CIBERONC grants to J.P.S. (CB16/12/00480), M.M.S. (CB16/12/00369) and B.V. (CB16/12/00233).

Published
2020

5. Post-transplant Cyclophosphamide in One-Antigen Mismatched Unrelated Donor Transplantation Versus Haploidentical Transplantation: A Retrospective Study on Behalf of The Acute Leukemia Working Party of The EBMT

Author

Battipaglia, Giorgia, Galimard, Jacques-Emmanuel, Labopin, Myriam, Angelucci, Emanuele, Didier Blaise, Ruggeri, Annalisa, Gulbas, Zafer, Luiz Diez-Martin, Jean, Koc, Yener, Castagna, Luca, Vitek, Antonin, Chiusolo, Patrizia, Bruno, Benedetto, Moiseev, Ivan, Rovira, Montserrat, Martino, Massimo, Colorado Araujo, Mercedes, Arat, Mutlu, Grillo, Giovanni, Martin, Hans, Lopez Corral, Lucia, Pane, Fabrizio, Bazarbachi, Ali, Ciceri, Fabio, Nagler, Arnon, and Mohty, Mohamad

Catalog

Books, media, physical & digital resources
See catalog results